Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities

Cancer Research

Volumn 66, Issue 23, 2006, Pages 11502-11513

  Maher, Elizabeth A ^a,c,h   Brennan, Cameron ^f   Wen, Patrick Y ^a,c   Durso, Laura ^a   Ligon, Keith L ^d   Richardson, Aaron ^a   Khatry, Deepak ^a   Feng, Bin ^a   Sinha, Raktim ^a   Louis, David N ^g   Quackenbush, John ^b,e   Black, Peter Mc L ^d   Chin, Lynda ^a,c,d   DePinho, Ronald A ^a,b,c  

^a Belfer Institute for Innovative Cancer Science   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COHORT ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; DNA MICROARRAY; GENE NUMBER; GENETIC ANALYSIS; GLIOBLASTOMA; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS;

ASTROCYTOMA; CHROMOSOME ABERRATIONS; CLUSTER ANALYSIS; DISEASE PROGRESSION; GENE DELETION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; GENOMICS; GLIOBLASTOMA; HUMANS; NUCLEIC ACID HYBRIDIZATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 33845807801     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-2072     Document Type: Article

References (48)

1. Kleihues P, Ohgaki H. Primary and secondary glioblastomas: from concept to clinical diagnosis. Neurooncol 1999;1:44-51.
2. Tso CL, Freije WA, Day A, et al. Distinct transcription profiles of primary and secondary glioblastoma subgroups. Cancer Res 2006;66:159-67.
3. Hui AB, Lo KW, Yin XL, Poon WS, Ng HK. Detection of multiple gene amplifications in glioblastoma multiforme using array-based comparative genomic hybridization. Lab Invest 2001;81:717-23.
4. Nigro JM, Misra A, Zhang L, et al. Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res 2005;65:1678-86.
5. Liang Y, Diehn M, Watson N, et al. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci U S A 2005;102:5814-9.
6. Nishizaki T, Kubota H, Harada K, et al. Clinical evidence of distinct subgroups of astrocytic tumors defined by comparative genomic hybridization. Hum Pathol 2000;31:608-14.
7. Quan AL, Barnett GH, Lee SY, et al. Epidermal growth factor receptor amplification does not have prognostic significance in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2005;63:695-703.
8. Rich JN, Hans C, Jones B, et al. Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res 2005;65:4051-8.
9. Burton EC, Lamborn KR, Feuerstein BG, et al. Genetic aberrations defined by comparative genomic hybridization distinguish long-term from typical survivors of glioblastoma. Cancer Res 2002;62:6205-10.
10. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFH kinase inhibitors. N Engl J Med 2005;353:2012-24.
11. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006;9:157-73.
12. Schmidt MC, Antweiler S, Urban N, et al. Impact of genotype and morphology on the prognosis of glioblastoma. J Neuropathol Exp Neurol 2002;61:321-8.
13. Tonon G, Wong KK, Maulik G, et al. High-resolution genomic profiles of human lung cancer. Proc Natl Acad Sci U S A 2005;102:9625-30.
14. Olshen AB, Venkatraman ES, Lucito R, Wigler M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 2004;5:557-72.
15. Carrasco DR, Tonon G, Huang Y, et al. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 2006;9:313-25.
16. Brunet JP, Tamayo P, Golub TR, Mesirov JP. Metagenes and molecular pattern discovery using matrix factorization. Proc Natl Acad Sci U S A 2004;101:4164-9.
17. Nutt CL, Mani DR, Betensky RA, et al. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 2003;63:1602-7.
18. Brennan C, Zhang Y, Leo C, et al. High-resolution global profiling of genomic alterations with long oligonucleotide microarray. Cancer Res 2004;64:4744-8.
19. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005;64:479-89.
20. Misra A, Pellarin M, Nigro J, et al. Array comparative genomic hybridization identifies genetic subgroups in grade 4 human astrocytoma. Clin Cancer Res 2005;11:2907-18.
21. Johansson FK, Brodd J, Eklof C, et al. Identification of candidate cancer-causing genes in mouse brain tumors by retroviral tagging. Proc Natl Acad Sci U S A 2004;101:11334-7.
22. Ciafre SA, Galardi S, Mangiola A, et al. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun 2005;334:1351-8.
23. Dunn M, Sinha P, Campbell R, et al. Co-expression of neuregulins 1, 2, 3 and 4 in human breast cancer. J Pathol 2004;203:672-80.
24. Bieche I, Lerebours F, Tozlu S, Espie M, Marty M, Lidereau R. Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature. Clin Cancer Res 2004;10:6789-95.
25. Miller CT, Aggarwal S, Lin TK, et al. Amplification and overexpression of the dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 (DYRK2) gene in esophageal and lung adenocarcinomas. Cancer Res 2003;63:4136-43.
26. Dunant NM, Wisniewski D, Strife A, Clarkson B, Resh MD. The phosphatidylinositol polyphosphate 5-phosphatase SHIP1 associates with the dokI phosphoprotein in bcr-Abl transformed cells. Cell Signal 2000;12:317-26.
27. Jung M, Romer A, Keyszer G, et al. mRNA expression of the five membrane-type matrix metalloproteinases MT1-MT5 in human prostatic cell lines and their downregulation in human malignant prostatic tissue. Prostate 2003;55:89-98.
28. Kuroyanagi H, Yan J, Seki N, et al. Human ULK1, a novel serine/threonine kinase related to UNC-51 kinase of Caenorhabditis elegans: cDNA cloning, expression, and chromosomal assignment. Genomics 1998;51:76-85.
29. Toraman AD, Keser I, Luleci G, Tunali N, Gelen T. Comparative genomic hybridization in ganglioneuroblastomas. Cancer Genet Cytogenet 2002;132:36-40.
30. Hughes S, Damato BE, Giddings I, Hiscott PS, Humphreys J, Houlston RS. Microarray comparative genomic hybridisation analysis of intraocular uveal melanomas identifies distinctive imbalances associated with loss of chromosome 3. Br J Cancer 2005;93:1191-6.
31. Tong CY, Hui AB, Yin XL, et al. Detection of oncogene amplifications in medulloblastomas by comparative genomic hybridization and array-based comparative genomic hybridization. J Neurosurg 2004;100:187-93.
32. Katoh Y, Katoh M. Identification and characterization of CDC50A, CDCS0B and CDC50C genes in silico. Oncol Rep 2004;12:939-43.
33. Belloni E, Trubia M, Mancini M, et al. A new complex rearrangement involving the ETV6, LOC115548, and MN1 genes in a case of acute myeloid leukemia. Genes Chromosomes Cancer 2004;41:272-7.
34. Huang DP, Lo KW Choi PH, et al. Loss of heterozygosity on the short arm of chromosome 3 in nasopharyngeal carcinoma. Cancer Genet Cytogenet 1991;54:91-9.
35. Morohara K, Nakao K, Tajima Y, et al. Analysis by comparative genomic hybridization of gastric cancer with peritoneal dissemination and/or positive peritoneal cytology. Cancer Genet Cytogenet 2005;161:57-62.
36. Bluteau O, Beaudoin JC, Pasturaud P, et al. Specific association between alcohol intake, high grade of differentiation and 4q34-q35 deletions in hepatocellular carcinomas identified by high resolution allelotyping. Oncogene 2002;21:1225-32.
37. Chow SN, Lin MC, Shen J, Wang S, Jong YJ, Chien CH. Analysis of chromosome abnormalities by comparative genomic hybridization in malignant peripheral primitive neuroectodermal tumor of the ovary. Gynecol Oncol 2004;92:752-60.
38. Natrajan R, Louhelainen J, Williams S, Laye J, Knowles MA. High-resolution deletion mapping of 15q13.2-q21.1 in transitional cell carcinoma of the bladder. Cancer Res 2003;63:7657-62.
39. Gordon A, McManus A, Anderson J, et al. Chromosomal imbalances in pleomorphic rhabdomyosarcomas and identification of the alveolar rhabdomyosarcoma-associated PAX3-FOXO1A fusion gene in one case. Cancer Genet Cytogenet 2003;140:73-7.
40. Wullich B, Sattler HP, Fischer U, Meese E. Two independent amplification events on chromosome 7 in glioma: amplification of the epidermal growth factor receptor gene and amplification of the oncogene MET. Anticancer Res 1994;14:577-9.
41. Lin M, Smith LT, Smiraglia DJ, et al. DNA copy number gains in head and neck squamous cell carcinoma. Oncogene 2006;25:1424-33.
42. Arai H, Ueno T, Tangoku A, et al. Detection of amplified oncogenes by genome DNA microarrays in human primary esophageal squamous cell carcinoma: comparison with conventional comparative genomic hybridization analysis. Cancer Genet Cytogenet 2003;146:16-21.
43. Rossi MR, Conroy J, McQuaid D, Nowak NJ, Rutka JT, Cowell JK. Array CGH analysis of pediatric medulloblastomas. Genes Chromosomes Cancer 2006;45:290-303.
44. Smeets SJ, Braakhuis BJ, Abbas S, et al. Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus. Oncogene 2006;25:2558-64.
45. Midorikawa Y, Tsutsumi S, Nishimura K, et al. Distinct chromosomal bias of gene expression signatures in the progression of hepatocellular carcinoma. Cancer Res 2004;64:7263-70.
46. Meng S, Chen Z, Munoz-Antonia T, Wu J. Participation of both Gab1 and Gab2 in the activation of the ERK/MAPK pathway by epidermal growth factor. Biochem J 2005;391:143-51.
47. Rich JN, Reardon DA, Peery T, et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004;22:133-42.
48. Maher EA, Furnari FB, Bachoo RM, et al. Malignant glioma: genetics and biology of a grave matter. Genes Dev 2001;15:1311-33.